Axsome Therapeutics, Inc. AXSM 深 沪
交易中 03-25 11:44:22 美东时间
161.23
+2.480
+1.56%
华盛通- 最 高163.48
- 今 开160.60
- 成交量 11.24万股
- 最 低 160.60
- 昨 收 158.75
- 总市值 82.47亿
- 52周最高 191.50
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 86.99
- 委 比 36.84%
- 总股本 5115.33万
- 历史最高 191.50
- 量 比 0.54
- 振 幅 1.81%
- 历史最低 1.94
- 每 手 1
- 风险率 27.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $245
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $220 to $245.
今天 20:44
Helus posts mid-stage trial data for anxiety disorder therapy
Helus Pharma (HELP) announced on Thursday that adults with generalized anxiety disorder who were taking part in a Phase 2 trial for its psychedelic-based therapy HLP004 improved symptoms with statisti...
03-05 21:18
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Issued on behalf of Helus Pharma VANCOUVER, BC, Feb. 26, 2026 /PRNewswire/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatm...
02-27 01:07
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics announced its participation in several March 2026 investor conferences, including the TD Cowen Health Care Conference on March 2, and the Leerink, Citizens, UBS Biotech Summit, and Jefferies Biotech on the Beach Summits in Miami Beach on March 9-11. Live webcasts for the TD Cowen, Leerink, and Citizens conferences will be available on the company’s website, with replays accessible for about 30 days. Axsome Therapeutics focuses...
02-25 12:00
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Wolfe Research Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $230
Wolfe Research analyst Rudy Li initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Outperform rating and announces Price Target of $230.
02-24 20:31
U.S. RESEARCH ROUNDUP-Dollar General, Keysight Technologies, Teledyne Technologies
U.S. RESEARCH ROUNDUP-Dollar General, Keysight Technologies, Teledyne Technologies Feb 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Dollar General, Keysight Technologies and Teledyne Technologies, on Tuesday. HIGHL
02-24 15:56
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
财报速睇 | Axsome Therapeutics, Inc. 2025财年Q4营收1.96亿美元，同比增长65.0%；归母净利润亏损0.29亿美元，同比亏损缩窄61.9%
华盛资讯2月23日讯，Axsome Therapeutics, Inc.公布2025财年Q4业绩，公司Q4营收1.96亿美元，同比增长65.0%，归母净利润亏损0.29亿美元，同比亏损缩窄61.9%。
02-23 20:32
Axsome Therapeutics Q4 revenue rises 65% driven by AUVELITY
Axsome Therapeutics Q4 revenue rises 65% driven by AUVELITY Overview Biopharmaceutical firm's Q4 revenue grew 65% yr/yr, driven by AUVELITY and SUNOSI Company reported net loss of $28.6 mln for Q4, narrowed from last year Company acquired AXS-17, expanding CNS disorder treatment pipeline Outlook Axs
02-23 20:08
